title: Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage.
authors.forename: Alan
authors.initials: A
authors.lastname: Moses
mesh_terms: D000208:Acute Disease; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D052216:Glucagon-Like Peptide 1 / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D054795:Incretins / Q000009:adverse effects* / Q000627:therapeutic use; D000069450:Liraglutide; D010179:Pancreas / Q000187:drug effects* / Q000473:pathology; D010195:Pancreatitis / Q000139:chemically induced*
chemical_list: D007004:Hypoglycemic Agents; D054795:Incretins; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1